The approval allows for dosing of Imcivree, or setmelanotide, in patients aged 6 years and older who have pro-opiomelanocortin or leptin receptor deficiency and kidney disease. The EC approved the drug last year for the treatment of obesity and hunger control.
The drugmaker said Imcivree is now available in Germany.
Rhythm Pharmaceuticals shares were down 1.4% in recent premarket trading Wednesday.
Price: 4.14, Change: -0.06, Percent Change: -1.43
|Sector Update: Consumer Stocks Continue to Add Suppo...|
|Insider Buy: Cincor Pharma|
|Sector Update: Energy Stocks Sink with Steep Drop by...|
|Supply-Side Constraints Continues to Improve in July...|
|Sector Update: Tech|